Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
:XERS
XERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.21 - $7.09
Previous CloseN/A
Volume530.95K
Average Volume (3M)2.31M
Market Cap
$1.10B
Enterprise Value$942.61M
Total Cash (Recent Filing)$58.44M
Total Debt (Recent Filing)$268.75M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding161,480,360
10 Day Avg. Volume3,018,180
30 Day Avg. Volume2,306,812
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue4.24
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda-108.88
Forecast
1Y Price Target
$7.10Price Target Upside3.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceXeris delivered strong revenues, representing around 48% year-over-year growth, marking another consecutive quarter of over 20% year-over-year growth.
Revenue GrowthRecord growth of Recorlev with revenue growing approximately 141% year-over-year, driven by a 124% increase in average patients on therapy.
Bears Say
Investor ConfidenceSome investors might still want more granular details on the roadmap for Recorlev becoming a blockbuster product, which could take some time.
Operational ExecutionXeris management provided an ambitious longer-term revenue outlook for the commercial portfolio and Recorlev specifically, including $750M total revenue by 2030 and $1B+ for Recorlev alone by 2035.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $2.21 and its highest was $7.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.10B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 87 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.018.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 161,480,360 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 20.219%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.10 (3.80% Upside)
$7.10 (3.80% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 763.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $109.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
206.72%
12-Months-Change
Fundamentals
Return on Equity
222.83%
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant revenue growth, a successful product portfolio, and strategic FDA approval. While there is an increase in SG&A expenses, the overall performance remains robust, supported by strong financial metrics and promising pipeline developments.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$7.10
▲(3.80% Upside)
Technical Analysis
Xencor
―
Zymeworks
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
Ownership Overview
6.00% Insiders
9.16% Mutual Funds
0.28% Other Institutional Investors
72.95% Public Companies and
Individual Investors